In 2024, we saw the expanded use of synthetic data and natural language processing transform drug discovery and development. In a batch of predictions published in December of 2023, one expert predicted that synthetic data was set to “take off” in drug research. In 2025, the pendulum could begin swinging back the other way, according…
New SEC rules and Cencora breach result in surge of pharma data breach disclosures
The pharmaceutical industry is grappling with the consequences of a significant data breach at Cencora, the prominent drug distributor formerly known as AmerisourceBergen. Recent cybersecurity rules from the U.S. Securities and Exchange Commissions (SEC), which came into effect in December 2023, have also played a role in a wave of data breach reports, highlighting the…
Best practices for data capture in long-term follow-up studies
Clinical trials and long-term follow-up studies (LTFUs) hinge on a whirlwind of data collection, where the volume and quality of patient data form the cornerstone of success. Erratic and patchy data can throw a monkey wrench into evaluating the potency and safety of cutting-edge drugs and devices. Such snags can drag approvals through the mud…